Serum High-Mobility Group Box 1 and Heme Oxygenase 1 as Biomarkers in COVID-19 Patients at Hospital Admission
2023
Autori:
Grigorov, IlijanaPejić, Snežana
Todorović, Ana
Drakulić, Dunja
Veljković, Filip
Miletić-Vukajlović, Jadranka
Bobić, Katarina
Soldatović, Ivan
Đurašević, Siniša
Jasnić, Nebojša
Stanković, Sanja
Glumac, Sofija
Mihailović-Vučinić, Violeta
Milenković, Branislava
Tip dokumenta:
Članak u časopisu (Objavljena verzija)
Metapodaci
Prikaz svih podataka o dokumentuApstrakt:
The careful monitoring of patients with mild/moderate COVID-19 is of particular importance because of the rapid progression of complications associated with COVID-19. For prognostic reasons and for the economic management of health care resources, additional biomarkers need to be identified, and their monitoring can conceivably be performed in the early stages of the disease. In this retrospective cross-sectional study, we found that serum concentrations of high-mobility group box 1 (HMGB1) and heme oxygenase-1 (HO-1), at the time of hospital admission, could be useful biomarkers for COVID-19 management. The study included 160 randomly selected recovered patients with mild to moderate COVID-19 on admission. Compared with healthy controls, serum HMGB1 and HO-1 levels increased by 487.6 pg/mL versus 43.1 pg/mL and 1497.7 pg/mL versus 756.1 pg/mL, respectively. Serum HO-1 correlated significantly with serum HMGB1, oxidative stress parameters (malondialdehyde (MDA), the phosphatidylcholine/lysophosphatidylcholine ratio (PC/LPC), the ratio of reduced and oxidative glutathione (GSH/GSSG)), and anti-inflammatory acute phase proteins (ferritin, haptoglobin). Increased heme catabolism/hemolysis were not detected. We hypothesize that the increase in HO-1 in the early phase of COVID-19 disease is likely to have a survival benefit by providing protection against oxidative stress and inflammation, whereas the level of HMGB1 increase reflects the activity of the innate immune system and represents levels within which the disease can be kept under control.
Ključne reči:
high-mobility group box 1(HMGB1); heme oxygenase-1 (HO-1); predictive biomarker; SARS-CoV-2; COVID-19Izvor:
International Journal of Molecular Sciences, 2023, 24, 17, 13164-Finansiranje / projekti:
- V.I.R.U.S. – Survivors of COVID19: variety of immune responses to SARS-CoV-2 in correlation with clinical manifestation. Long term follow up (RS-ScienceFundRS-Fond_2020_COVID19-7551587)
- Ministarstvo nauke, tehnološkog razvoja i inovacija Republike Srbije, institucionalno finansiranje - 200007 (Univerzitet u Beogradu, Institut za biološka istraživanja 'Siniša Stanković') (RS-MESTD-inst-2020-200007)
- Ministarstvo nauke, tehnološkog razvoja i inovacija Republike Srbije, institucionalno finansiranje - 200017 (Univerzitet u Beogradu, Institut za nuklearne nauke Vinča, Beograd-Vinča) (RS-MESTD-inst-2020-200017)
- Ministarstvo nauke, tehnološkog razvoja i inovacija Republike Srbije, institucionalno finansiranje - 200178 (Univerzitet u Beogradu, Biološki fakultet) (RS-MESTD-inst-2020-200178)
DOI: 10.3390/ijms241713164
ISSN: 1661-6596
PubMed: 37685970